Teva Offers Update On Operations In Israel

Expects Current Conflict To Have No ‘Meaningful Impact’ On Business

Amid war in Israel, local generics industry giant Teva has indicated that it sees no “meaningful impact” on its business from the conflict, while highlighting that it is prioritizing the importance of its employees and patients.

Teva building
Teva has provided an update on its operations in Israel • Source: Shutterstock

Israeli firm Teva has provided an update on its domestic operations amid the ongoing conflict in the home country of one of the off-patent industry’s largest players.

Thousands of deaths and widespread disruption have followed in the aftermath of the attacks that began on 7 October by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

Sandoz Strikes $300m Deal With Just-Evotec For French Biosimilars Site

 
• By 

Sandoz has made yet another major move to further bolster its booming biosimilars business, striking a $300m deal to acquire outright a French development and manufacturing facility from existing biosimilars partner Just-Evotec Biologics.

Celltrion Nears Deal For US Biologics Plant To Quell Tariff Concerns

 
• By 

Celltrion is the preferred bidder for the acquisition of a large-scale cGMP biologics manufacturing plant in the US, marking a pivotal move to localize production and secure its US pharmaceutical business against rising tariff risks.

FDA Inspection Finds Leaks and Mold at Sun Pharma Halol Facility

 
• By 

Sun Pharma is facing renewed scrutiny after a scathing US Food and Drug Administration inspection at its Halol facility in Gujarat painted a grim picture of a facility operating in disregard of basic pharmaceutical safety standards.

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

More from Business

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

Teva: Not All Our Biosimilars Need To Be Superstars

 
• By 

With eight biosimilars launching by 2027, Teva sees its biosimilars business not as a one-hit bet, but a portfolio approach. The company spoke about its plans, alongside tariffs and other topics, during its second-quarter earnings call.

BC Partners Bids For Biogaran Buyout – But Will It Face French Pushback?

 
• By 

Private equity firm BC Partners has revealed that it is in exclusive negotiations to acquire Servier’s French generics and biosimilars business Biogaran. But with France’s government having expressed opposition to the sale, could there be strings attached?